A method for separating and determining impurities in flurbiprofen axetil injection by correction factor method based on HPLC
Through HPLC calibration factor method and high-performance liquid chromatography, the problem of detection of multiple impurities in flubiprofen ester injection was solved, and efficient qualitative and quantitative analysis of 10 impurities was achieved, which improved the accuracy of drug quality control and Security.
Patent Information
- Application Number
- CN202410270766.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-08
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-03-08
AI Technical Summary
The existing quality standards of flubiprofen ester injection lack comprehensive monitoring of various impurities, resulting in drug quality and safety risks. The existing detection methods are insufficient in specificity and cannot effectively detect multiple known impurities.
Using HPLC-based calibration factor method, 10 impurities in flubiprofen ester injection were simultaneously determined by high performance liquid chromatography. Thermo BDS Hypersil C18 chromatography column was used, and the mobile phase was a 0.15% aqueous glacial acetic acid solution and acetonitrile. The gradient was washed Deprogramming and correction factor calculations enable qualitative and quantitative analysis.
It realizes effective separation and accurate quantitative analysis of impurities in flubiprofen ester injection. The method has high sensitivity and strong specificity, and can quickly and accurately monitor a variety of known impurities, improving the accuracy and safety of drug quality control sex.
Smart Images

Figure CN118191177B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical analysis, and in particular relates to a method for separating and determining impurities in flurbiprofen axetil injection by a correction factor method based on HPLC. Background Art
[0002] As a nonsteroidal antiinflammatory drug (NSAID), flurbiprofen axetil can non-selectively inhibit cyclooxygenase, thereby blocking the synthesis of prostaglandins and exerting analgesic, anti-inflammatory and antipyretic effects. Flurbiprofen axetil injection is a lipid microsphere of flurbiprofen axetil encapsulated by lecithin. After entering the body, the drug can be targeted and distributed in trauma and tumor tissues, and hydrolyzed by carboxylesterase to produce flurbiprofen, thereby exerting an analgesic effect. At present, it is commonly used in clinical practice to relieve pain caused by surgery and cancer. In recent years, adverse reactions of flurbiprofen have been reported during clinical application, and the adverse reactions of the injection are closely related to drug impurities. Therefore, in order to improve the safety of flurbiprofen axetil injection, strict, comprehensive and accurate quality control of its related substances is required.
[0003] However, there are few reports on impurity detection of flurbiprofen axetil injection. On the other hand, the related substance detection method of the current domestic quality standard of flurbiprofen axetil injection is limited to the detection of known impurities in flurbiprofen, lacks comprehensive monitoring of other known impurities, has defects in specificity and accuracy, and is seriously insufficient in monitoring and controlling impurities, posing huge risks to drug quality and safety. Therefore, it is urgent to establish a related substance detection method with stronger specificity and higher accuracy to improve drug safety. Summary of the invention
[0004] In view of the technical gap in the prior art, the present invention provides a method for separating and determining impurities in flurbiprofen axetil injection based on the correction factor method of HPLC, establishes a novel high performance liquid chromatography (HPLC) method that can simultaneously determine 10 related impurities, and through methodological verification, achieves effective separation and accurate quantification of related substances in the preparation.
[0005] The technical solution adopted by the present invention to achieve the above-mentioned purpose is:
[0006] The present invention provides a method for separating and determining impurities in flurbiprofen axetil injection by a correction factor method based on HPLC, comprising the following steps:
[0007] (1) Reference solution: Take flurbiprofen and flurbiprofen axetil reference substances, add anhydrous ethanol to prepare flurbiprofen and flurbiprofen axetil solutions, respectively, take appropriate amounts of each, and dilute with a diluent to prepare flurbiprofen reference solution and flurbiprofen axetil reference solution;
[0008] (2) Test solution: dilute flurbiprofen axetil with a diluent to obtain a test solution;
[0009] (3) Stock solutions of impurity reference substances: Take appropriate amounts of 10 impurity reference substances, weigh them accurately, and dissolve them in anhydrous ethanol to prepare stock solutions;
[0010] (4) The HPLC correction factor method was used to qualitatively and quantitatively determine the impurities.
[0011] Furthermore, in step (1), the concentrations of the flurbiprofen reference solution and the flurbiprofen axetil reference solution are both 1 mg / mL.
[0012] Furthermore, in step (2), the concentration of the test solution is 1 mg / mL.
[0013] Furthermore, in step (1) or (2), the diluent is composed of mobile phase A and mobile phase B in a volume ratio of 1:2; mobile phase A is an aqueous solution containing 0.15% glacial acetic acid, and mobile phase B is acetonitrile containing 0.15% glacial acetic acid.
[0014] Further, in step (3), the impurities are 2-(2-fluoro-4-hydroxy)biphenyl (4-OHB), 4-acetyl-2-fluorobiphenyl (4-ACB), 1-acetoxyethyl-2-(2-fluoro-4-biphenyl)-2-hydroxypropionate (2-OHP), allyl-(2-fluoro-4-biphenyl) propionate (ALE), flurbiprofen, 2-(2-fluoro-4-biphenyl)-ethyl propionate (flurbiprofen ethyl ester), 2-(4-biphenyl) propionic acid (Chp impurity I), 2-(2-fluoro-[1,1'-biphenyl]-4-yl)-2,3-dimethylsuccinic acid (impurity B), 2-([1,1,-biphenyl-4-yl])-2-hydroxypropionic acid (impurity C), and 2-fluorobiphenyl-4-carboxylic acid (impurity E).
[0015] Furthermore, in step (3), the concentration of the stock solution is 1 mg / ml.
[0016] In the detection method provided by the present invention, the conditions of the high performance liquid chromatography adopted are: the chromatographic column is ThermoBDS Hypersil C18, 250×4.6mm, 5μm; the flow rate is 1.0ml / min; the temperature is 40°C; the column detection wavelength is 254nm; the injection volume is 10μl; the mobile phase is: A is an aqueous solution containing 0.15% glacial acetic acid, and B is acetonitrile containing 0.15% glacial acetic acid.
[0017] The program of the above gradient elution is: 0-20.0 min, 40%-47% B; 20.0-24.0 min, 47%-60% B; 24.0-37.5 min, 60% B; 37.5-38.0 min, 60%-40% B; 38.0-48.0 min, 40% B.
[0018] Furthermore, the correction factors of the impurities 4-OHB, 2-OHP, 4-ACB, flurbiprofen ethyl, ALE, Chp impurity I, impurity B, impurity C, and impurity E are 0.55, 1.05, 1.01, 0.95, 0.86, 0.55, 0.93, 0.76, and 0.81, respectively.
[0019] The present invention adopts HPLC correction factor method to determine the related substances of flurbiprofen axetil injection. Thermo BDS Hypersil C18 (250×4.6mm, 5μm) chromatographic column is adopted, and gradient elution is carried out with acetonitrile containing 0.15% glacial acetic acid aqueous solution and 0.15% glacial acetic acid as mobile phase, the flow rate is 1.0ml / min, the column temperature is 40℃, and the detection wavelength is 254nm. The results show that flurbiprofen axetil and 10 impurities can be effectively separated, and each impurity has a good linear relationship with the peak area within the mass concentration range of 0.10-20μg / ml, and the correlation coefficient r is 1.0000, and the average recovery rate of each impurity is between 96.6% and 103.7%, and the relative standard deviation (RSD) of the recovery rate does not exceed 1.4%. The correction factors of impurities 4-OHB, 2-OHP, 4-ACB, flurbiprofen ethyl ester, ALE, Chp impurity I, impurity B, impurity C, and impurity E are 0.55, 1.05, 1.01, 0.95, 0.86, 0.55, 0.93, 0.76, and 0.81, respectively.
[0020] The beneficial effects of the present invention are:
[0021] (1) The present invention locates the related substances of flurbiprofen axetil injection by using the external standard method of reference substances, thereby calculating the relative retention time of each impurity to qualitatively characterize the impurities in the test sample, and establishes a principal component external standard method with a correction factor to quantitatively analyze the impurities of the related substances of flurbiprofen axetil injection.
[0022] (2) This method can be used to qualitatively and quantitatively analyze a variety of known impurities in the test sample without the need for impurity reference substances. It is rapid, simple, highly sensitive, specific, accurate and reliable, and provides technical support for the production process control and quality monitoring of flurbiprofen axetil injection. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 is the solvent chromatogram;
[0024] Figure 2 is the chromatogram of the impurity reference solution;
[0025] Figure 3 is the chromatogram of the test solution;
[0026] Figure 4 The chromatogram was destroyed by 1mol1mol / L hydrochloric acid;
[0027] Figure 5 The chromatogram was destroyed by 0.5 mol / L NaOH;
[0028] Figure 6 The chromatogram is oxidative destruction;
[0029] Figure 7 for light-destroyed chromatograms;
[0030] Figure 8 High temperature destroys the chromatogram
[0031] Fig. 9 The frequency distribution diagram (left) and box plot (right) of the flurbiprofen test results;
[0032] Fig.10 The frequency distribution diagram (left) and box plot (right) of 2-OHP determination results;
[0033] Fig.11 The frequency distribution diagram (left) and box plot (right) of the 4-ACB test results;
[0034] Fig.12 The frequency distribution diagram (left) and box plot (right) of the determination results of the sum of other impurities. DETAILED DESCRIPTION
[0035] The technical solution of the present invention is further explained and illustrated by means of specific embodiments below.
[0036] Example 1
[0037] 1 Experimental part
[0038] 1.1 Instruments, reagents and test drugs
[0039] Thermo Ultimate 3000 high performance liquid chromatograph (Thermo, USA), Mettler XS205 electronic (Mettler Toledo, Switzerland).
[0040] Flurbiprofen axetil and its impurity reference substance information: Flurbiprofen axetil (content: 99.8%, China National Institute for Food and Drug Control), Flurbiprofen (content: 99.7%, China National Institute for Food and Drug Control), 4-OHB (2-fluoro-4-hydroxybiphenyl, content: 98.13%, Shenzhen Hengfeng Wanda Pharmaceutical Technology Co., Ltd.), 4-ACB (4-acetyl-2-fluorobiphenyl, content: 97.62%, Shenzhen Hengfeng Wanda Pharmaceutical Technology Co., Ltd.), 2-OHP (1-acetoxy-2-(2-fluoro-4-biphenyl)-2-hydroxypropionate, content: 97.73%, Shenzhen Hengfeng Wanda Pharmaceutical Technology Co., Ltd.), ALE (allyl-(2-fluoro-4-biphenyl) propionate, content: 99.86%, Shenzhen Hengfeng Wanda Pharmaceutical Technology Co., Ltd.), flurbiprofen ethyl ester (content: 99.56%, Shenzhen Hengfeng Wanda Pharmaceutical Technology Co., Ltd.), Chp impurity I (content: 100%, China National Institute for Inspection), EP impurity B (content: 96.02%, Shenzhen Hengfeng Wanda Pharmaceutical Technology Co., Ltd.), EP impurity C (content: 99.14%, Shenzhen Hengfeng Wanda Pharmaceutical Technology Co., Ltd.), EP impurity E (content: 98.14%, Shenzhen Hengfeng Wanda Pharmaceutical Technology Co., Ltd.); chromatographic grade acetonitrile and methanol were purchased from Merck (USA), glacial acetic acid (purity> 99%) was purchased from Fisher (USA); 18.2MΩ·cm purified water for the experiment was prepared by Millipore Milli-Q Advantage A10 ultrapure water system (Millipore, USA). The samples came from two domestic manufacturers A and B, totaling 73 batches.
[0041] 1.2 Solution preparation
[0042] 1.2.1 Specific test solution
[0043] Control (undamaged): Take about 50 mg of flurbiprofen axetil API, weigh accurately, and dilute to 10 ml with anhydrous ethanol;
[0044] Acid: Take about 50 mg of flurbiprofen axetil API (three portions), weigh accurately, add 5 ml of anhydrous ethanol to dissolve, then add 1 ml of 0.2, 0.5 and 1 mol / L HCl solution respectively, neutralize with alkali after 24 hours, and make up to 10 ml with anhydrous ethanol;
[0045] Base: Take about 50 mg of flurbiprofen axetil API (three portions), weigh accurately, add 5 ml of anhydrous ethanol to dissolve, then add 1 ml of 0.2, 0.5 and 1 mol / L NaOH solution respectively, neutralize with acid after 24 hours, and make up to 10 ml with anhydrous ethanol;
[0046] Oxidation: Take about 50 mg of flurbiprofen axetil API, weigh accurately, add 5 ml of anhydrous ethanol to dissolve, then add 2 ml of 30% hydrogen peroxide, oxidize for 24 hours, and dilute to 10 ml with anhydrous ethanol;
[0047] High temperature: Take about 50 mg of flurbiprofen axetil API, weigh accurately, heat in a water bath at 80°C for 24 hours, and dilute to 10 ml with anhydrous ethanol;
[0048] Irradiation: Take about 50 mg of flurbiprofen axetil API, weigh accurately, irradiate with visible light intensity of 4000 lx for 24 hours, and dilute to 10 ml with anhydrous ethanol.
[0049] 1.2.2 Reference solution Take appropriate amount of flurbiprofen and flurbiprofen axetil reference substances, add anhydrous ethanol to prepare solutions containing 1 mg per 1 ml, take appropriate amount of each, dilute with mobile phase to prepare solutions containing 10 μg of flurbiprofen and 1.0 μg of flurbiprofen axetil per 1 ml, as reference solutions.
[0050] 1.2.3 Test solution Take an appropriate amount of the product and dilute it with mobile phase to make a test solution containing approximately 1 mg of flurbiprofen axetil per 1 ml.
[0051] 1.2.4 Stock solutions of impurity reference substances Take appropriate amount of each impurity (10 kinds) reference substance, weigh accurately, add anhydrous ethanol to dissolve and prepare stock solutions with a concentration of about 1 mg / ml.
[0052] 1.3 Chromatographic conditions
[0053] The chromatographic column was Thermo BDS Hypersil C18 (250×4.6mm, 5μm), the flow rate was 1.0ml / min; the temperature was 40°C; the column detection wavelength was 254nm; the injection volume was 10μl. Mobile phase: A was an aqueous solution containing 0.15% glacial acetic acid, and B was acetonitrile containing 0.15% glacial acetic acid. Gradient elution program: 0-20.0min, 40%-47% B; 20.0-24.0min, 47%-60% B; 24.0-37.5min, 60% B; 37.5-38.0min, 60%-40% B; 38.0-48.0min, 40% B.
[0054] Effect Example 1
[0055] (1) Optimization of chromatographic conditions
[0056] During the experiment, the inventors found that when the original mobile phase system (acetonitrile-water-glacial acetic acid = 675:325:1.5) or (acetonitrile-water-glacial acetic acid = 1200:800:3) was used, the separation between some adjacent impurities was poor, and even overlapped, that is, the separation between the main component and each related impurity could not meet the requirements at the same time, and the system applicability was poor. In conjunction with the 10 kinds of related impurities to be tested in the present invention (the molecular structures of the compounds are shown in Table 1), there are problems such as a large number of impurities, dispersed polarity (phenols, carboxylic acids, ketones, carboxylic acid esters and other compounds containing aromatic structures), and some impurities with close polarity (flurbiprofen axetil and its ethyl ester). In terms of optimizing the chromatographic conditions, the original mobile phase composition system was retained, and different types and brands of chromatographic columns (AgilentZORBAX XDB-C 18 , Kromasil 100-5-C 18 ,Thermo BDS Hypersil-C 18 ), by adjusting the elution time and the organic phase ratio, the analysis time was shortened to meet the separation degree between each component ≥ 1.5, and the elution procedure was finally determined, see "1.3 Chromatographic Conditions". The results showed that the separation degree between the 10 known impurities and the main component met the requirements, thus achieving qualitative and quantitative analysis of multiple known impurities.
[0057] Table 1 Molecular structure of flurbiprofen axetil and its impurities
[0058]
[0059] (2) Methodological validation
[0060] ① Exclusiveness
[0061] Use strong acid, strong alkali, oxidation, light, and high temperature conditions to conduct a destructive test on flurbiprofen axetil. Take each solution and mobile phase under "1.2.1" as a blank solution, inject samples according to the chromatographic conditions under "1.3", and record the chromatogram (such as Figure 4-Figure 8As shown). The test results show that the raw material of flurbiprofen axetil remains stable under high temperature (80℃ water bath), light and oxidation conditions, and the impurities are basically unchanged, and no degradation products are found. However, it will undergo obvious degradation under acid and alkaline conditions, and the main degradation product is flurbiprofen, which is produced by the hydrolysis of the ester bond of flurbiprofen axetil. The experiment found that flurbiprofen axetil is more sensitive to alkaline conditions than acidic conditions, and 0.2mol / L NaOH can cause almost complete hydrolysis of flurbiprofen axetil. In addition, the same obvious degradation peak appeared at the same retention time in the chromatogram destroyed by alkali (0.2mol / L NaOH) and the chromatogram destroyed by acid (1mol / L hydrochloric acid); some weaker degradation peaks were added to the chromatogram destroyed by alkali (0.5mol / L NaOH). The above chromatogram results show that after flurbiprofen axetil is destroyed by acid and alkali, the peaks of each degradation product are well separated from the main peak, the blank solvent has no interference with the detection, and the method has good specificity.
[0062] ②Determination of linear range and correction factor
[0063] Take appropriate amount of solution under "1.2.4" respectively, dilute 7 standard curve solutions with concentrations of 0.10-20μg / ml (flurbiprofen concentration of 0.10-100μg / ml) with mobile phase, and operate according to the method of "1.3". Perform linear regression of peak area with concentration for flurbiprofen axetil and each impurity, calculate the correction factor of impurity by the ratio of the linear slope of flurbiprofen axetil to the linear slope of each impurity, and calculate the relative retention time. The main component and each impurity have a good linear relationship within their respective concentration ranges, and the correlation coefficient r is 1.0000. Detailed results are shown in Table 2. The chromatogram of the impurity reference solution is shown in Figure 2 shown.
[0064] Table 2 Correction factors and other information of each impurity in flurbiprofen axetil
[0065]
[0066] ③Limit of quantification and limit of detection
[0067] Take the linear solutions of 4-OHB, 2-OHP, 4-ACB, flurbiprofen, flurbiprofen ethyl ester, ALE, Chp impurity I, impurity B, impurity C, and impurity E with a concentration of about 0.1 μg / ml under item ②, dilute them step by step, calculate the limit of quantification according to S / N≈10, and calculate the limit of detection according to S / N≈3. The concentration range of the limit of quantification of the above impurities is 0.025~0.10μg / ml, and the concentration range of the limit of detection is 0.01~0.04μg / ml, see Table 3 for details.
[0068] Table 3 Quantitative limits and detection limits of impurities in flurbiprofen axetil
[0069]
[0070] ④Accuracy and precision
[0071] Prepare 7 test solutions according to the method of "1.2.3", and accurately add 1 ml of the reference solution with a flurbiprofen concentration of about 740 μg / mL and the concentration of other impurities of about 10 μg / mL to 6 of them, so as to obtain the test solution for the recovery test. According to the method under "1.3", the peak area of each impurity is determined, and the average recovery rate and RSD results are calculated. The results show that the recovery rate of each impurity is in the range of 96.6% to 103.7%, indicating that the accuracy and precision of the method are good.
[0072] ⑤Durability
[0073] When the column temperature of the liquid chromatograph was adjusted to 35℃ and 45℃, and the flow rate was adjusted to 0.9ml / min and 1.0ml / min, the peak shape of the chromatogram remained basically unchanged, the chromatographic retention time changed slightly, the theoretical plate number and the separation degree remained basically unchanged, and the separation degree between each compound was greater than 1.5. The results show that a slight change in the determination conditions can meet the requirements of the system suitability test, does not affect the detection of each compound, and the method is reliable.
[0074] Effect Example 2 Sample Determination
[0075] A total of 73 batches of samples produced by two domestic companies A and B were taken, and the test solutions were prepared according to the method under "1.2.3". The samples were injected and measured according to the chromatographic conditions under "1.3". The main component external standard method with correction factors was used for calculation. The results are shown in Table 4. The representative test solution chromatogram is shown in Figure 3 The detected amount of each impurity meets the proposed limit regulations (flurbiprofen shall not exceed 0.74 mg / ml, and other individual impurities shall not exceed 0.1%).
[0076] Table 4 Results of determination of impurity detection
[0077]
[0078] The highest detected known impurities of both companies are flurbiprofen. Overall, the mean values of flurbiprofen detected are relatively close, but the 25% to 75% quantile and 1.5 IQR (interquartile range) of company B are significantly better than those of company A, indicating that the detected amount of company B is concentrated near the mean and the data dispersion is small. Therefore, company B has better quality control of flurbiprofen, better production process control of flurbiprofen axetil injection, and the dispersion of flurbiprofen detected between batches is significantly lower than that of samples from company A. Fig. 9 (Red: Company A, blue: Company B). In addition to flurbiprofen, the largest known impurity detected in the samples was 2-OHP, which was detected in all 73 batches of samples and the detection amount was not less than 0.02%, see Fig.10 ; Only 6 batches of samples from Company A were found to contain 4-ACB impurities, and the amount detected was very low, all at 0.002%. In contrast, 4-ACB was detected in all 32 batches of samples from Company B, with the results ranging from 0.01 to 0.04%. Fig.11 ; In addition, the detection amounts of flurbiprofen ethyl ester, ALE, impurity B, impurity C, and Chp impurity I in the samples of the two companies were all at extremely low levels (<0.01%). The detection amounts of other largest single impurities in 41 batches of samples of Company A were between 0.03% and 0.05%, and the detection amounts of other largest single impurities in 32 batches of samples of Company B were between 0.02% and 0.03%. The sum of all impurities except flurbiprofen in 41 batches of samples of Company A was between 0.18% and 0.31%, and that in 32 batches of samples of Company B was between 0.24% and 0.35%. Fig.12 .
[0079] Based on the test results of 73 batches of samples from two domestic manufacturers A and B, the types of known impurities and the detected values of the two companies are generally equivalent, and the test results meet the requirements. Among them, the detection amount of flurbiprofen in the two companies is the largest, and the overall detection amount of company B is slightly lower than that of company A. In addition, the detection amount of company B is concentrated near the mean, and the data dispersion is small. In contrast, the production process of flurbiprofen axetil injection of company B is more stable and the quality control is better.
Claims
1. A method for separating and determining impurities in flurbiprofen axetil injection using a correction factor method based on HPLC, It is characterized in that The following steps are involved: (1) Reference solution: Take flurbiprofen and flurbiprofen axetil reference substances, add anhydrous ethanol to prepare flurbiprofen and flurbiprofen axetil solutions, respectively; take appropriate amount of each, dilute with diluent to prepare flurbiprofen reference solution and flurbiprofen axetil reference solution; (2) Test solution: dilute flurbiprofen axetil with a diluent to obtain a test solution; (3) Stock solutions of impurity reference substances: Take appropriate amounts of 10 impurity reference substances, weigh them accurately, and dissolve them in anhydrous ethanol to prepare stock solutions; (4) Use HPLC correction factor method to qualitatively and quantitatively determine impurities; In step (1) or (2), the diluent is composed of mobile phase A and mobile phase B in a volume ratio of 1:2; In step (4), the conditions of the high performance liquid chromatography method used for the determination are as follows: the chromatographic column is Thermo BDS HypersilC18, 250×4.6 mm, 5 μm; the flow rate is 1.0 ml / min; the column temperature is 40°C; the detection wavelength is 254 nm; the injection volume is 10 μl; the mobile phase A is an aqueous solution containing 0.15% glacial acetic acid, and the mobile phase B is acetonitrile containing 0.15% glacial acetic acid; gradient elution; The gradient elution program was as follows: 0-20.0 min, 40%-47% B; 20.0-24.0 min, 47%-60% B; 24.0-37.5 min, 60% B; 37.5-38.0 min, 60%-40% B; 38.0-48.0 min, 40% B; In step (3), the impurities are 2-(2-fluoro-4-hydroxy)biphenyl, 4-acetyl-2-fluorobiphenyl, 1-acetoxyethyl-2-(2-fluoro-4-biphenyl)-2-hydroxypropionate, allyl-(2-fluoro-4-biphenyl) propionate, flurbiprofen, 2-(2-fluoro-4-biphenyl)-ethyl propionate, 2-(4-biphenyl) propionic acid, 2-(2-fluoro-[1,1'-biphenyl]-4-yl)-2,3-dimethylsuccinic acid, 2-([1,1,-biphenyl-4-yl])-2-hydroxypropionic acid, and 2-fluorobiphenyl-4-carboxylic acid.
2. The method according to claim 1, It is characterized in that In step (1), the concentrations of the flurbiprofen reference solution and the flurbiprofen axetil reference solution are both 1 mg / mL.
3. The method according to claim 1, It is characterized in that In step (2), the concentration of the test solution is 1 mg / mL.
4. The method according to claim 1, It is characterized in that In step (3), the concentration of the stock solution is 1 mg / ml.
5. The method according to any one of claims 1 to 4, It is characterized in that The correction factors of the impurities 2-(2-fluoro-4-hydroxy)biphenyl, 1-acetoxyethyl-2-(2-fluoro-4-biphenyl)-2-hydroxypropionate, 4-acetyl-2-fluorobiphenyl, 2-(2-fluoro-4-biphenyl)-ethyl propionate, allyl-(2-fluoro-4-biphenyl) propionate, 2-(4-biphenyl) propionic acid, 2-(2-fluoro-[1,1'-biphenyl]-4-yl)-2,3-dimethylsuccinic acid, 2-([1,1,-biphenyl-4-yl])-2-hydroxypropionic acid, and 2-fluorobiphenyl-4-carboxylic acid are 0.55, 1.05, 1.01, 0.95, 0.86, 0.55, 0.93, 0.76, and 0.81, respectively.
